PPMD welcomes Dr. Padraig Wright from GlaxoSmithKline as our guest for a webinar on February 22, 2012 at 1pm eastern.
- Topic: Exon Skipping
- When: Wednesday, February 22, 1pm eastern
About
GSK2402968 is an antisense oligonucleotide being developed by GlaxoSmithKline as a potential treatment for boys with Duchenne who have mutations/deletions that can be treated with exon 51 “skipping.” This presentation will describe the current clinical development program, with particular focus on the recruiting studies in ambulant boys with DMD: DMD114044 and the recently initiated US long-term study, DMD114876.
To Participate
Unfortunately GSK will not allow us to record this webinar, so we will not be able to provide you with a link to replay the presentation afterwards. Please make sure to join us LIVE at 1pm eastern so you don't miss out!

PPMD Blog
Read more PPMD Blogs
You need to be a member of PPMD Community to add comments!
Join PPMD Community